The best of news in cancer

I've been on an impromptu vacation this week so am just catching up with some cancer news I missed. Here's the best of it:

Lancet published some interesting Letters to the Editor about the insulin glargine–cancer connection, arguing that there are other sides to this association to be considered.
As I think I have pointed out before, cancer mortality rates continue to decline, and the bulk of the progress has been made in pediatric malignancies (this is, I think, a very good thing, to steal a line from Martha Stewart).
JAMA published a prospective cohort study on aspirin use and survival after colorectal cancer, showing improved survival. But the bulk of the benefit was among patients whose tumors expressed COX-2.
In a very well-done prospective, randomized, controlled clinical trial, a program of progressive weight lifting prevented worsened swelling of the affected limb in breast cancer survivors with lymphedema and may also prevent future exacerbations (Also read the accompanying editorial.).
Cetuximab has been found to not be cost-effective relative to benefit among KRAS wild-type patients.